Search for "mode of action" in Full Text gives 90 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2016, 12, 1428–1433, doi:10.3762/bjoc.12.137
Graphical Abstract
Figure 1: BHL and OdDHL are two natural AHL-based signaling molecules used by P. aeruginosain quorum sensing....
Scheme 1: Unexpected synthesis of compound 4. The synthesis of 2 was achieved by a previously reported route [9]....
Figure 2: a) Inhibitory effect of compound 4 (200 μM suspension in DMSO) on pyocyanin production in PAO1. DMS...
Figure 3: Binding poses of OdDHL and compound 4 in OdDHL binding site. Hydrogen bonds are shown in black dott...
Beilstein J. Org. Chem. 2016, 12, 969–984, doi:10.3762/bjoc.12.96
Graphical Abstract
Figure 1: Structures of cystobactamids 507, 919-1 and 919-2.
Figure 2: Structures of aurafuron A and corallopyronin A.
Figure 3: Structures of ixabepilone and capecitabine.
Figure 4: Structures of DKxanthene-534 and myxochelin A.
Figure 5: Phylogenetic tree of halotolerant and halophilic myxobacteria. The neighbor-joining tree is based o...
Figure 6: Structure of nannocystin A.
Figure 7: Structure of phenylnannolones A–C.
Figure 8: Structures of the pyrronazols, dihydroxyphenazin and 1-hydroxyphenazin-6-yl-α-D-arabinofuranoside.
Figure 9: Structures of nannozinones A + B and nannochelin A from N. pusilla strain MNa10913.
Figure 10: Structure of haliangicin from H. ochraceum.
Figure 11: Structure of haliamide from H. ochraceum SMP-2.
Figure 12: Structures of salimabromide, enhygrolides A + B and salimyxins A + B.
Figure 13: Structures of miuraenamides A–F from P. miuraensis.
Beilstein J. Org. Chem. 2016, 12, 769–795, doi:10.3762/bjoc.12.77
Graphical Abstract
Figure 1: Structures of the naturally occurring muraymycins isolated by McDonald et al. [22].
Figure 2: Structures of selected classes of nucleoside antibiotics. Similarities to the muraymycins are highl...
Figure 3: Structure of peptidoglycan. Long chains of glycosides (alternating GlcNAc (green) and MurNAc (blue)...
Figure 4: Schematic representation of bacterial cell wall biosynthesis.
Figure 5: Translocase I (MraY) catalyses the reaction of UDP-MurNAc-pentapeptide with undecaprenyl phosphate ...
Figure 6: Proposed mechanisms for the MraY-catalysed reaction. A: Two-step mechanism postulated by Heydanek e...
Scheme 1: First synthetic access towards simplified muraymycin analogues as reported by Yamashita et al. [76].
Scheme 2: Synthesis of (+)-caprazol (19) reported by Ichikawa, Matsuda et al. [92].
Scheme 3: Synthesis of the epicapreomycidine-containing urea dipeptide via C–H activation [96,97].
Scheme 4: Synthesis of muraymycin D2 and its epimer reported by Ichikawa, Matsuda et al. [96,97].
Scheme 5: Synthesis of the urea tripeptide unit as a building block for muraymycins reported by Kurosu et al. ...
Scheme 6: Synthesis of the uridine-derived core structure of naturally occuring muraymycins reported by Ducho...
Scheme 7: Synthesis of the epicapreomycidine-containing urea dipeptide from Garner's aldehyde reported by Duc...
Scheme 8: Synthesis of a hydroxyleucine-derived aldehyde building block reported by Ducho et al. [107].
Scheme 9: Synthesis of 5'-deoxy muraymycin C4 (65) as a closely related natural product analogue [78,109,110].
Figure 7: Summary of modifications on semisynthetic muraymycin analogues tested by Lin et al. [86]. Most active c...
Figure 8: Bioactive muraymycin analogues identified by Yamashita et al. [76].
Figure 9: Muraymycin D2 and several non-natural lipidated analogues 91a–d [77,114].
Figure 10: Non-natural muraymycin analogues with varying peptide structures [77,114].
Figure 11: SAR results for several structural variations of the muraymycin scaffold.
Figure 12: Muraymycin analogues designed for potential anti-Pseudomonas activity (most active analogues are hi...
Scheme 10: Proposed outline pathway for muraymycin biosynthesis based on the analysis of the biosynthetic gene...
Scheme 11: Biosynthesis of the nucleoside core structure of A-90289 antibiotics (which is identical to the mur...
Scheme 12: Transaldolase-catalysed formation of the key intermediate GlyU 101 in the biosynthesis of muraymyci...
Beilstein J. Org. Chem. 2016, 12, 594–607, doi:10.3762/bjoc.12.58
Graphical Abstract
Figure 1: Natural products isolated from M. xanthus DK1622. DKxanthene-534 (1); myxalamid B (2); myxovirescin...
Figure 2: Vegetative cells of P. fallax HKI 727 under a phase-contrast microscope (K. Martin, unpublished). B...
Figure 3: Structures of myxopyronins A (11) and B (12), corallopyronins A (13), B (14) and C (15), as well as...
Figure 4: Structure of althiomycin (17).
Figure 5: Structures of cystobactamids 919-1 (18), 919-2 (19), and 507 (20).
Figure 6: Structures of natural products isolated from Herpetosiphon spp.: siphonazole (21); auriculamide (22...
Beilstein J. Org. Chem. 2015, 11, 2540–2548, doi:10.3762/bjoc.11.274
Graphical Abstract
Figure 1: The author as a teenager in his school uniform, but on the nearby Myrtleford golf course.
Scheme 1: Chronological progression of Smith group research projects.
Scheme 2: Molecular transporters promote translocation of ions or hydrophilic biomolecules across a synthetic...
Figure 2: (left) Association of ZnDPA probe with phosphatidylserine head group. (middle) False colored fluore...
Scheme 3: Macrocyclic receptor that binds solvent separated ion-pairs.
Scheme 4: Trapping a macrocyclic receptor containing a reactive ion-pair produces an interlocked [2]rotaxane.
Figure 3: (left) General structure of a squaraine rotaxane dye. (right) Fluorescence image of a living mouse ...
Scheme 5: (top) Basis of Synthavidin technology. A fluorescent squaraine dye that is flanked by PEG chains ca...
Figure 4: The author as director of the Notre Dame Integrated Imaging Facility.
Beilstein J. Org. Chem. 2015, 11, 1656–1666, doi:10.3762/bjoc.11.182
Graphical Abstract
Figure 1: Sterically demanding benzannulated NHCs bearing mesityl rings. From the left side:, 4,9-dihydro-4,9...
Figure 2: Benzannulated NHCs of this work. Benzannulated imidazolium chloride salts 1-Cl, 2-Cl, 3-Cl and 4-Cl...
Scheme 1: Synthesis of the N1,N2-diaryl-1,2-benzenediamines 5, 6, 7 and 8. i) Pd(dba)2, P(t-Bu)3, t-BuONa, to...
Scheme 2: Previous synthesis of the benzannulated NHCs 3-Cl and 4-BF4. Ring closure. i) (EtO)3CH, HCl (conc.)...
Scheme 3: Proposed ring-closure mechanism for 1-Cl, 2-Cl, 3-Cl and 4-Cl.
Figure 3: Molecular structure of 2-Cl. The solvate molecule, the counterion and the hydrogen atoms are omitte...
Beilstein J. Org. Chem. 2015, 11, 659–667, doi:10.3762/bjoc.11.74
Graphical Abstract
Figure 1: N-Bu DNJ (1) and examples of potent multivalent pharmacological chaperones and CFTR correctors (2 a...
Figure 2: Azide-armed DNJ derivatives 4 and polyalkyne “clickable” scaffolds 5 and 6.
Scheme 1: Synthesis of trisubstituted BODIPY derivatives. (a) ICl, CHCl3/MeOH, rt, 15 min, quantitative; (b) ...
Scheme 2: Synthesis of DNJ clusters 13: (a) CuSO4·5H2O cat., sodium ascorbate, THF/H2O (1:1), 83% (12a), 56% (...
Scheme 3: Synthesis of DNJ clusters 15: (a) CuSO4·5H2O cat., sodium ascorbate, DMF/H2O (6:1), 80 °C (MW) or r...
Figure 3: a) Absorption (orange line), corrected emission (green line) (λexc = 510 nm), excitation (dashed bl...
Figure 4: a) Absorption (orange line), corrected emission (green line) (λexc = 360 nm) and excitation (dashed...
Beilstein J. Org. Chem. 2015, 11, 249–264, doi:10.3762/bjoc.11.28
Graphical Abstract
Figure 1: Structure of 4-hydroxybenzyl alcohol (HBA, 1).
Figure 2: Structure–activity relationship of curcumin analogs.
Scheme 1: Synthesis of curcumin (3). Reagents and conditions: (a) vanillin, 1,2,3,4-tetrahydroquinoline, HOAc...
Figure 3: Backbone and substitution of monocarbonyl analogs of curcumin (MACs) showing their structural diver...
Scheme 2: Exemplary synthesis of MAC representatives. Reagents and conditions: (a) 40% KOH, EtOH, 5 °C; stirr...
Scheme 3: Synthesis of ellagic acid (7). Reagents and conditions: (a) H2SO4, CH3OH; (b) (1) o-chloranil, Et2O...
Figure 4: Structure of resveratrol and its analogs.
Scheme 4: Synthesis of quinolone-substituted phenol 20. Reagents and conditions: (a) Ac2O, 2-hydroxybenzaldeh...
Scheme 5: Synthesis of quinolone-substituted phenol 23. Reagents and conditions: (a) Ac2O, 2-hydroxybenzaldeh...
Figure 5: Design of 4-amino-2-sulfanylphenol derivatives and their structure–activity relationship.
Scheme 6: Synthesis of 4-amino-2-sulfanylphenol derivatives. Reagents and conditions: (a) R1SO2Cl, pyridine, ...
Figure 6: Structures of two series of natural-like acylphloroglucinols.
Scheme 7: Synthesis of acylphloroglucinol derivatives 35–41. Reagents and conditions: (a) acyl chloride, AlCl3...
Scheme 8: Synthesis of acylphloroglucinol derivatives 43–51. Reagents and conditions: (a) isoprene, Amberlyst...
Figure 7: Analogs of (−)-EGCG for the prevention of oxidation and improvement of the bioavailability of the c...
Scheme 9: Synthesis of xanthohumol 58. Reagents and conditions: (a) MOMCl, diisopropylethylamine, CH2Cl2; (b)...
Scheme 10: Synthesis of genistein 60. Reagents and conditions: (a) 4-hydroxyphenylacetonitrile, anhydrous HCl,...
Scheme 11: Synthesis of fisetin (67) and quercetin (68). Reagents and conditions: (a) 3,4-dimethoxybenzaldehyd...
Figure 8: Structure of (2S)-7,2’,4’-trihydroxy-5-methoxy-8-(dimethylallyl)flavanone (69).
Beilstein J. Org. Chem. 2014, 10, 2603–2622, doi:10.3762/bjoc.10.273
Graphical Abstract
Scheme 1: Principle of resistance mechanisms through selection of the most resistant micro-organism.
Figure 1: Chemical structure of carbendazim.
Scheme 2: Chemical structure of benomyl and its decomposition in aqueous solution.
Figure 2: Chemical structure of enilconazole.
Figure 3: Chemical structure of chloramidophos.
Scheme 3: The complex problem of pentachlorophenol (PCP) degradation.
Figure 4: Chemical structure of DCPE.
Figure 5: Chemical structures of some biocides used in [59].
Figure 6: Chemical structure of miconazole nitrate.
Figure 7: Chemical structures of triclosan and butylparaben.
Figure 8: Chemical structure of ciprofloxacin hydrochloride.
Figure 9: Chemical structure of benzethonium chloride.
Figure 10: Chemical structure of benzalkonium chlorides.
Scheme 4: Multiple equilibria of CD with benzalkonium chloride (BZK) and fluorometholone.
Scheme 5: Competition between co-micellization and biocidal activity observed for didecyldimethylammonium chl...
Scheme 6: Proposed antimicrobial mechanism of encapsulated didecyldimethylammonium chloride by CDs: (1) diffu...
Scheme 7: Inhibition of co-micellization process observed for didecyldimethylammonium chloride, octaethyleneg...
Scheme 8: Schematic representation of biocide release from a chemically cross-linked CD network.
Scheme 9: Proposed Trojan horse mechanism of silver nanoparticles capped by β-CD.
Scheme 10: Proposed mechanism of copper nanoparticles immobilized on carbon nanotube and embedded in water-ins...
Scheme 11: Advantages and drawback of the physicochemical and biopharmaceutical properties of CDs/biocides inc...
Beilstein J. Org. Chem. 2014, 10, 2531–2538, doi:10.3762/bjoc.10.264
Graphical Abstract
Scheme 1: Synthesis of Nortricyclenes from Norbornenes.
Figure 1: X-ray crystal structure of 5a with 30% thermal ellipsoids.
Scheme 2: KO2-mediated synthesis of tetrachloro-substituted 3-methylenenortricyclenes. Reaction conditions: A...
Scheme 3: Mechanism investigations.
Scheme 4: Plausible mechanism of the KO2-mediated reaction.
Figure 2: X-ray crystal structure of 8a with 30% thermal ellipsoids.
Scheme 5: Plausible mechanism of the acylation reaction of 3-methylenenortricyclenes.
Beilstein J. Org. Chem. 2014, 10, 2470–2479, doi:10.3762/bjoc.10.258
Graphical Abstract
Figure 1: Structure of the reporter molecule BPT (1).
Scheme 1: Synthesis of the azide-bearing 4-hydroxythiazole derivative 1.
Figure 2: Structure of the tested azide-modified standard fluorophores DNS (8) and NBD (9) and the bromine mo...
Figure 3: UV–vis spectra of 20 µM solutions of the azide modified fluorophores BPT (1), DNS (8), NBD (9) and ...
Figure 4: Normalized absorbance and fluorescence of BPT (1) in 20% THF/80% water (v/v), excitation at 374 nm.
Figure 5: Peak area of 100 pmol BPT (1), DNS (8), NBD (9) and BNS (6) measured with (A) C18-UPLC coupled to a...
Figure 6: Procedure of the model reaction between L-lysine and DDY (10) to form an imine (only one of two pos...
Figure 7: Mass spectra of labeled L-lysine/DDY (10)/fluorophore conjugates 11 (containing BPT), 12 (containin...
Figure 8: Fluorescent labeling of catalase treated with DDY (10) followed by CuAAC with all four reporter mol...
Beilstein J. Org. Chem. 2014, 10, 1999–2012, doi:10.3762/bjoc.10.208
Graphical Abstract
Figure 1: Structures of RF and its photoproducts.
Figure 2: A general scheme for the photodegradation of RF in aqueous solution.
Figure 3: log k–pH profiles for the photolysis of RF in aqueous solution using UV light (∆) and visible light...
Figure 4: log k–pH profiles for the photolysis of FMF (10−4 M) in alkaline solution under aerobic (○) and ana...
Figure 5: k'–pH profiles for the photolysis of FMF (10−4 M) in acidic solution under aerobic (○) and anaerobi...
Figure 6: Plots of k` versus pH for phosphate (▲) and sulfate (●) anion-catalyzed photodegradation of RF (5 ×...
Figure 7: log kobs–pH profiles for the photolysis of RF (5 × 10−5 M) in 0.1–0.5 M borate buffer. Experimental...
Figure 8: log kobs–pH profiles for the photolysis of RF (5 × 10−5 M) in 0.2–1.0 M citrate buffer. Experimenta...
Figure 9: k'–pH profile for the photolysis of RF (5 × 10−5 M) in the presence of CF (0.5–2.5 × 10−4 M). Exper...
Beilstein J. Org. Chem. 2014, 10, 1796–1801, doi:10.3762/bjoc.10.188
Graphical Abstract
Figure 1: TDA and related natural products from Phaeobacter inhibens.
Scheme 1: Synthesis of tropone-2-carboxylic acid (13).
Scheme 2: Synthesis of halogenated TDA analogues.
Scheme 3: Further compounds included in this SAR study.
Beilstein J. Org. Chem. 2014, 10, 1064–1096, doi:10.3762/bjoc.10.106
Graphical Abstract
Scheme 1: Synthesis of P-stereogenic phosphines 5 using menthylphosphinite borane diastereomers 2.
Scheme 2: Enantioselective synthesis of chiral phosphines 10 with ephedrine as a chiral auxiliary.
Scheme 3: Chlorophosphine boranes 11a as P-chirogenic electrophilic building blocks.
Scheme 4: Monoalkylation of phenylphosphine borane 15 with methyl iodide in the presence of Cinchona alkaloid...
Scheme 5: Preparation of tetraphosphine borane 19.
Scheme 6: Using chiral chlorophosphine-boranes 11b as phosphide borane 20 precursors.
Scheme 7: Nickel-catalyzed cross-coupling (dppe = 1,2-bis(diphenylphosphino)ethane).
Scheme 8: Pd-catalyzed cross-coupling reaction with organophosphorus stannanes 30.
Scheme 9: Copper iodide catalyzed carbon–phosphorus bond formation.
Scheme 10: Thermodynamic kinetic resolution as the origin of enantioselectivity in metal-catalyzed asymmetric ...
Scheme 11: Ru-catalyzed asymmetric phosphination of benzyl and alkyl chlorides 35 with HPPhMe (36a, PHOX = pho...
Scheme 12: Pt-catalyzed asymmetric alkylation of secondary phosphines 36b.
Scheme 13: Different adducts 43 can result from hydrophosphination.
Scheme 14: Pt-catalyzed asymmetric hydrophosphination.
Scheme 15: Intramolecular hydrophosphination of phosphinoalkene 47.
Scheme 16: Organocatalytic asymmetric hydrophosphination of α,β-unsaturated aldehydes 59.
Scheme 17: Preparation of phosphines using zinc organometallics.
Scheme 18: Preparation of alkenylphosphines 71a from alkenylzirconocenes 69 (dtc = N,N-diethyldithiocarbamate,...
Scheme 19: SNAr with P-chiral alkylmethylphosphine boranes 13c.
Scheme 20: Synthesis of QuinoxP 74 (TMEDA = tetramethylethylenediamine).
Scheme 21: Pd-Mediated couplings of a vinyl triflate 76 with diphenylphosphine borane 13e.
Figure 1: Menthone (83) and camphor (84) derived chiral phosphines.
Scheme 22: Palladium-catalyzed cross-coupling reaction of vinyl tosylates 85 and 87 with diphenylphosphine bor...
Scheme 23: Attempt for the enantioselective palladium-catalyzed C–P cross-coupling reaction between an alkenyl...
Scheme 24: Enol phosphates 88 as vinylic coupling partners in the palladium-catalyzed C–P cross-coupling react...
Scheme 25: Nickel-catalyzed cross-coupling in the presence of zinc (dppe = 1,2-bis(diphenylphosphino)ethane).
Scheme 26: Copper-catalyzed coupling of secondary phosphines with vinyl halide 94.
Scheme 27: Palladium-catalyzed cross-coupling of aryl iodides 97 with organoheteroatom stannanes 30.
Scheme 28: Synthesis of optically active phosphine boranes 100 by cross-coupling with a chiral phosphine boran...
Scheme 29: Palladium-catalyzed P–C cross-coupling reactions between primary or secondary phosphines and functi...
Scheme 30: Enantioselective synthesis of a P-chirogenic phosphine 108.
Scheme 31: Enantioselective arylation of silylphosphine 110 ((R,R)-Et-FerroTANE = 1,1'-bis((2R,4R)-2,4-diethyl...
Scheme 32: Nickel-catalyzed arylation of diphenylphosphine 25d.
Scheme 33: Nickel-catalyzed synthesis of (R)-BINAP 116 (dppe = 1,2-bis(diphenylphosphino)ethane, DABCO = 1,4-d...
Scheme 34: Nickel-catalyzed cross-coupling between aryl bromides 119 and diphenylphosphine (25d) (dppp = 1,3-b...
Scheme 35: Stereocontrolled Pd(0)−Cu(I) cocatalyzed aromatic phosphorylation.
Scheme 36: Preparation of alkenylphosphines by hydrophosphination of alkynes.
Scheme 37: Palladium and nickel-catalyzed addition of P–H to alkynes 125a.
Scheme 38: Palladium-catalyzed asymmetric hydrophosphination of an alkyne 128.
Scheme 39: Ruthenium catalyzed hydrophosphination of propargyl alcohols 132 (cod = 1,5-cyclooctadiene).
Scheme 40: Cobalt-catalyzed hydrophosphination of alkynes 134a (acac = acetylacetone).
Scheme 41: Tandem phosphorus–carbon bond formation–oxyfunctionalization of substituted phenylacetylenes 125c (...
Scheme 42: Organolanthanide-catalyzed intramolecular hydrophosphination/cyclization of phosphinoalkynes 143.
Scheme 43: Hydrophosphination of alkynes 134c catalyzed by ytterbium-imine complexes 145 (hmpa = hexamethylpho...
Scheme 44: Calcium-mediated hydrophosphanylation of alkyne 134d.
Scheme 45: Formation and substitution of bromophosphine borane 151.
Scheme 46: General scheme for a nickel or copper catalyzed cross-coupling reaction.
Scheme 47: Copper-catalyzed synthesis of alkynylphosphines 156.
Beilstein J. Org. Chem. 2014, 10, 316–322, doi:10.3762/bjoc.10.29
Graphical Abstract
Figure 1: Structures of the strongly cytotoxic marine natural products malevamide D (1), isodolastatin H (2),...
Scheme 1: Total synthesis of malevamide D (1). a) DMSO (16 equiv), NEt3 (5 equiv), pyridine·SO3 (5 equiv), 0 ...
Scheme 2: Formation of oxazolylphosphate 18 on attempted DEPC-mediated coupling of dipeptide 15.
Scheme 3: Synthesis of tosyloximes (Z)-22 and (E)-22, X-ray structure of (E)-22. a) NH2OH·HCl (1.5 equiv), py...
Scheme 4: Synthesis of photo malevamide D 30. a) NH3(l), t-BuOMe, −40 °C, 2 h, rt, 16 h, quant. b) I2 (1.2 eq...
Figure 2: DSC curve of diazirine 25, heating rate 5 °C/min.
Beilstein J. Org. Chem. 2014, 10, 194–208, doi:10.3762/bjoc.10.15
Graphical Abstract
Figure 1: Structures of the 4,4,8-trimethyl-17-furanylsteroid core structure I and the representative B-seco ...
Scheme 1: Retrosynthetic analysis of the B-seco limonoid framework employing a [3,3]-sigmatropic rearrangemen...
Scheme 2: Retrosynthetic analysis of the B-seco limonoid scaffold employing a Claisen rearrangement as key st...
Scheme 3: Synthesis of alcohols 19, 20 and 22. Reagents and conditions: a) CSA, 2,3-butanedione, trimethyl or...
Scheme 4: Retrosynthetic analysis of the B-seco limonoid scaffold employing an Ireland–Claisen rearrangement ...
Scheme 5: Synthesis and Ireland–Claisen rearrangement of the allyl esters 27, 28, 29 and 30. Reagents and con...
Figure 2: Conformation of rearrangement precursor 30 and possible transition state involved in the Ireland–Cl...
Scheme 6: Synthesis of model C rings 40, 41 and 42. Reagents and conditions: a) TBDPSCl, DMAP, NEt3, CH2Cl2, ...
Scheme 7: β-Substituted allyl esters tested in the Ireland–Claisen and the Carroll rearrangement.
Scheme 8: Synthesis and Ireland–Claisen rearrangement of bicyclic allyl ester precursor 66. Reagents and cond...
Figure 3: Conformations of rearrangement precursors 66 and 77 and possible transition states involved in the ...
Scheme 9: Synthesis and Ireland–Claisen rearrangement of allyl ester 70. Reagents and conditions: a) DIPEA, M...
Scheme 10: Synthesis and Ireland–Claisen rearrangement of allyl ester 72. Reagents and conditions: a) TIPSOTf,...
Scheme 11: Synthesis of the C14-epi and C14/C9-epi B-seco limonoid scaffolds 78 and 79. Reagents and condition...
Scheme 12: Synthesis of fully functionalized A ring 87. Reagents and conditions: a) HO(CH2)2OH, THF, Pd/C, H2,...
Scheme 13: and Attempted Ireland–Claisen rearrangement of allyl ester 88. R1 = MOM, R2 = CO2H.
Scheme 14: Synthesis and attempted Ireland–Claisen rearrangement of allyl ester 93. Reagents and conditions: a...
Scheme 15: Allyl esters tested in the Ireland–Claisen rearrangement.
Beilstein J. Org. Chem. 2014, 10, 163–193, doi:10.3762/bjoc.10.14
Graphical Abstract
Scheme 1: Vogel’s first approach towards the divinylcyclopropane rearrangement [4] and characterization of cis-d...
Scheme 2: Transition states for the Cope rearrangement and the related DVCPR. Ts = transition state.
Scheme 3: Two possible mechanisms of trans-cis isomerizations of divinylcyclopropanes.
Scheme 4: Proposed biosynthesic pathway to ectocarpene (21), an inactive degradation product of a sexual pher...
Scheme 5: Proposed biosynthesis of occidenol (25) and related natural compounds.
Scheme 6: Gaich’s bioinspired system using the DVCPR to mimick the dimethylallyltryptophan synthase. DMAPP = ...
Scheme 7: Iguchi’s total synthesis of clavubicyclone, part 1.
Scheme 8: Iguchi’s total synthesis of clavubicyclone, part 2.
Scheme 9: Wender’s syntheses of the two pseudoguainanes confertin (50) and damsinic acid (51) and Pier’s appr...
Scheme 10: Overman’s total synthesis of scopadulcic acid B.
Scheme 11: Davies’ total syntheses of tremulenolide A and tremulenediol A.
Scheme 12: Davies formal [4 + 3] cycloaddition approach towards the formal synthesis of frondosin B.
Scheme 13: Davies and Sarpongs formal [4 + 3]-cycloaddition approach towards barekoxide (106) and barekol (107...
Scheme 14: Davies formal [4 + 3]-cycloaddition approach to 5-epi-vibsanin E (115) containing an intermediate c...
Scheme 15: Echavarren’s total synthesis of schisanwilsonene A (126) featuring an impressive gold-catalzed casc...
Scheme 16: Davies early example of a formal [4 + 3]-cycloaddition in alkaloids synthesis.
Scheme 17: Fukuyama’s total synthesis of gelsemine, part 1.
Scheme 18: Fukuyama’s total synthesis of gelsemine, featuring a divinylcyclopropane rearrangement, part 2.
Scheme 19: Kende’s total synthesis of isostemofoline, using a formal [4 + 3]-cycloaddition, including an inter...
Scheme 20: Danishefsky’s total synthesis of gelsemine, part 1.
Scheme 21: Danishefsky’s total synthesis of gelsemine, part 2.
Scheme 22: Fukuyama’s total synthesis of gelsemoxonine.
Scheme 23: Wender’s synthetic access to the core skeleton of tiglianes, daphnanes and ingenanes.
Scheme 24: Davies’ approach towards the core skeleton of CP-263,114 (212).
Scheme 25: Wood’s approach towards actinophyllic acid.
Scheme 26: Takeda’s approach towards the skeleton of the cyanthins, utilitizing the divinylcyclopropane rearra...
Scheme 27: Donaldson’s organoiron route towards the guianolide skeleton.
Scheme 28: Stoltz’s tandem Wolff/DVCPR rearrangement.
Scheme 29: Stephenson’s tandem photocatalysis/arylvinylcyclopropane rearrangement.
Scheme 30: Padwa’s rhodium cascade involving a DVCPR.
Scheme 31: Matsubara’s version of a DVCPR.
Scheme 32: Toste’s tandem gold-catalyzed Claisen-rearrangement/DVCPR.
Scheme 33: Ruthenium- and gold-catalyzed versions of tandem reactions involving a DVCPR.
Scheme 34: Tungsten, platinum and gold catalysed cycloisomerizations leading to a DVCPR.
Scheme 35: Reisman’s total synthesis of salvileucalin B, featuring an (undesired) vinylcyclopropyl carbaldehyd...
Scheme 36: Studies on the divinylepoxide rearrangement.
Scheme 37: Studies on the vinylcyclopropanecarbonyl rearrangement.
Scheme 38: Nitrogen-substituted variants of the divinylcyclopropane rearrangement.
Beilstein J. Org. Chem. 2014, 10, 34–114, doi:10.3762/bjoc.10.6
Graphical Abstract
Figure 1: Five and six-membered cyclic peroxides.
Figure 2: Artemisinin and semi-synthetic derivatives.
Scheme 1: Synthesis of 3-hydroxy-1,2-dioxolanes 3a–c.
Scheme 2: Synthesis of dioxolane 6.
Scheme 3: Photooxygenation of oxazolidines 7a–d with formation of spiro-fused oxazolidine-containing dioxolan...
Scheme 4: Oxidation of cyclopropanes 10a–e and 11a–e with preparation of 1,2-dioxolanes 12a–e.
Scheme 5: VO(acac)2-catalyzed oxidation of silylated bicycloalkanols 13a–c.
Scheme 6: Mn(II)-catalyzed oxidation of cyclopropanols 15a–g.
Scheme 7: Oxidation of aminocyclopropanes 20a–c.
Scheme 8: Synthesis of aminodioxolanes 24.
Figure 3: Trifluoromethyl-containing dioxolane 25.
Scheme 9: Synthesis of 1,2-dioxolanes 27a–e by the oxidation of cyclopropanes 26a–e.
Scheme 10: Photoinduced oxidation of methylenecyclopropanes 28.
Scheme 11: Irradiation-mediated oxidation.
Scheme 12: Application of diazene 34 for dioxolane synthesis.
Scheme 13: Mn(OAc)3-catalyzed cooxidation of arylacetylenes 37a–h and acetylacetone with atmospheric oxygen.
Scheme 14: Peroxidation of (2-vinylcyclopropyl)benzene (40).
Scheme 15: Peroxidation of 1,4-dienes 43a,b.
Scheme 16: Peroxidation of 1,5-dienes 46.
Scheme 17: Peroxidation of oxetanes 53a,b.
Scheme 18: Peroxidation of 1,6-diene 56.
Scheme 19: Synthesis of 3-alkoxy-1,2-dioxolanes 62a,b.
Scheme 20: Synthesis of spiro-bis(1,2-dioxolane) 66.
Scheme 21: Synthesis of dispiro-1,2-dioxolanes 68, 70, 71.
Scheme 22: Synthesis of spirohydroperoxydioxolanes 75a,b.
Scheme 23: Synthesis of spirohydroperoxydioxolane 77 and dihydroperoxydioxolane 79.
Scheme 24: Ozonolysis of azepino[4,5-b]indole 80.
Scheme 25: SnCl4-mediated fragmentation of ozonides 84a–l in the presence of allyltrimethylsilane.
Scheme 26: SnCl4-mediated fragmentation of bicyclic ozonide 84m in the presence of allyltrimethylsilane.
Scheme 27: MCl4-mediated fragmentation of alkoxyhydroperoxides 96 in the presence of allyltrimethylsilane.
Scheme 28: SnCl4-catalyzed reaction of monotriethylsilylperoxyacetal 108 with alkene 109.
Scheme 29: SnCl4-catalyzed reaction of triethylsilylperoxyacetals 111 with alkenes.
Scheme 30: Desilylation of tert-butyldimethylsilylperoxy ketones 131a,b followed by cyclization.
Scheme 31: Deprotection of peroxide 133 followed by cyclization.
Scheme 32: Asymmetric peroxidation of methyl vinyl ketones 137a–e.
Scheme 33: Et2NH-catalyzed intramolecular cyclization.
Scheme 34: Synthesis of oxodioxolanes 143a–j.
Scheme 35: Haloperoxidation accompanied by intramolecular ring closure.
Scheme 36: Oxidation of triterpenes 149a–d with Na2Cr2O7/N-hydroxysuccinimide.
Scheme 37: Curtius and Wolff rearrangements to form 1,2-dioxolane ring-retaining products.
Scheme 38: Oxidative desilylation of peroxide 124.
Scheme 39: Synthesis of dioxolane 158, a compound containing the aminoquinoline antimalarial pharmacophore.
Scheme 40: Diastereomers of plakinic acid A, 162a and 162b.
Scheme 41: Ozonolysis of alkenes.
Scheme 42: Cross-ozonolysis of alkenes 166 with carbonyl compounds.
Scheme 43: Ozonolysis of the bicyclic cyclohexenone 168.
Scheme 44: Cross-ozonolysis of enol ethers 172a,b with cyclohexanone.
Scheme 45: Griesbaum co-ozonolysis.
Scheme 46: Reactions of aryloxiranes 177a,b with oxygen.
Scheme 47: Intramolecular formation of 1,2,4-trioxolane 180.
Scheme 48: Formation of 1,2,4-trioxolane 180 by the reaction of 1,5-ketoacetal 181 with H2O2.
Scheme 49: 1,2,4-Trioxolane 186 with tetrazole fragment.
Scheme 50: 1,2,4-Trioxolane 188 with a pyridine fragment.
Scheme 51: 1,2,4-Trioxolane 189 with pyrimidine fragment.
Scheme 52: Synthesis of aminoquinoline-containing 1,2,4-trioxalane 191.
Scheme 53: Synthesis of arterolane.
Scheme 54: Oxidation of diarylheptadienes 197a–c with singlet oxygen.
Scheme 55: Synthesis of hexacyclinol peroxide 200.
Scheme 56: Oxidation of enone 201 and enenitrile 203 with singlet oxygen.
Scheme 57: Synthesis of 1,2-dioxanes 207 by oxidative coupling of carbonyl compounds 206 and alkenes 205.
Scheme 58: 1,2-Dioxanes 209 synthesis by co-oxidation of 1,5-dienes 208 and thiols.
Scheme 59: Synthesis of bicyclic 1,2-dioxanes 212 with aryl substituents.
Scheme 60: Isayama–Mukaiyama peroxysilylation of 1,5-dienes 213 followed by desilylation under acidic conditio...
Scheme 61: Synthesis of bicycle 218 with an 1,2-dioxane ring.
Scheme 62: Intramolecular cyclization with an oxirane-ring opening.
Scheme 63: Inramolecular cyclization with the oxetane-ring opening.
Scheme 64: Intramolecular cyclization with the attack on a keto group.
Scheme 65: Peroxidation of the carbonyl group in unsaturated ketones 228 followed by cyclization of hydroperox...
Scheme 66: CsOH and Et2NH-catalyzed cyclization.
Scheme 67: Preparation of peroxyplakoric acid methyl ethers A and D.
Scheme 68: Hg(OAc)2 in 1,2-dioxane synthesis.
Scheme 69: Reaction of 1,4-diketones 242 with hydrogen peroxide.
Scheme 70: Inramolecular cyclization with oxetane-ring opening.
Scheme 71: Inramolecular cyclization with MsO fragment substitution.
Scheme 72: Synthesis of 1,2-dioxane 255a, a structurally similar compound to natural peroxyplakoric acids.
Scheme 73: Synthesis of 1,2-dioxanes based on the intramolecular cyclization of hydroperoxides containing C=C ...
Scheme 74: Use of BCIH in the intramolecular cyclization.
Scheme 75: Palladium-catalyzed cyclization of δ-unsaturated hydroperoxides 271a–e.
Scheme 76: Intramolecular cyclization of unsaturated peroxyacetals 273a–d.
Scheme 77: Allyltrimethylsilane in the synthesis of 1,2-dioxanes 276a–d.
Scheme 78: Intramolecular cyclization using the electrophilic center of the peroxycarbenium ion 279.
Scheme 79: Synthesis of bicyclic 1,2-dioxanes.
Scheme 80: Preparation of 1,2-dioxane 286.
Scheme 81: Di(tert-butyl)peroxalate-initiated radical cyclization of unsaturated hydroperoxide 287.
Scheme 82: Oxidation of 1,4-betaines 291a–d.
Scheme 83: Synthesis of aminoquinoline-containing 1,2-dioxane 294.
Scheme 84: Synthesis of the sulfonyl-containing 1,2-dioxane.
Scheme 85: Synthesis of the amido-containing 1,2-dioxane 301.
Scheme 86: Reaction of singlet oxygen with the 1,3-diene system 302.
Scheme 87: Synthesis of (+)-premnalane А and 8-epi-premnalane A.
Scheme 88: Synthesis of the diazo group containing 1,2-dioxenes 309a–e.
Figure 4: Plakortolide Е.
Scheme 89: Synthesis of 6-epiplakortolide Е.
Scheme 90: Application of Bu3SnH for the preparation of tetrahydrofuran-containing bicyclic peroxides 318a,b.
Scheme 91: Application of Bu3SnH for the preparation of lactone-containing bicyclic peroxides 320a–f.
Scheme 92: Dihydroxylation of the double bond in the 1,2-dioxene ring 321 with OsO4.
Scheme 93: Epoxidation of 1,2-dioxenes 324.
Scheme 94: Cyclopropanation of the double bond in endoperoxides 327.
Scheme 95: Preparation of pyridazine-containing bicyclic endoperoxides 334a–c.
Scheme 96: Synthesis of 1,2,4-trioxanes 337 by the hydroperoxidation of unsaturated alcohols 335 with 1O2 and ...
Scheme 97: Synthesis of sulfur-containing 1,2,4-trioxanes 339.
Scheme 98: BF3·Et2O-catalyzed synthesis of the 1,2,4-trioxanes 342a–g.
Scheme 99: Photooxidation of enol ethers or vinyl sulfides 343.
Scheme 100: Synthesis of tricyclic peroxide 346.
Scheme 101: Reaction of endoperoxides 348a,b derived from cyclohexadienes 347a,b with 1,4-cyclohexanedione.
Scheme 102: [4 + 2]-Cycloaddition of singlet oxygen to 2Н-pyrans 350.
Scheme 103: Synthesis of 1,2,4-trioxanes 354 using peroxysilylation stage.
Scheme 104: Epoxide-ring opening in 355 with H2O2 followed by the condensation of hydroxy hydroperoxides 356 wi...
Scheme 105: Peroxidation of unsaturated ketones 358 with the H2O2/CF3COOH/H2SO4 system.
Scheme 106: Synthesis of 1,2,4-trioxanes 362 through Et2NH-catalyzed intramolecular cyclization.
Scheme 107: Reduction of the double bond in tricyclic peroxides 363.
Scheme 108: Horner–Wadsworth–Emmons reaction in the presence of peroxide group.
Scheme 109: Reduction of ester group by LiBH4 in the presence of 1,2,4-trioxane moiety.
Scheme 110: Reductive amination of keto-containing 1,2,4-trioxane 370.
Scheme 111: Reductive amination of keto-containing 1,2,4-trioxane and a Fe-containing moiety.
Scheme 112: Acid-catalyzed reactions of Н2О2 with ketones and aldehydes 374.
Scheme 113: Cyclocondensation of carbonyl compounds 376a–d using Me3SiOOSiMe3/CF3SO3SiMe3.
Scheme 114: Peroxidation of 4-methylcyclohexanone (378).
Scheme 115: Synthesis of symmetrical tetraoxanes 382a,b from aldehydes 381a,b.
Scheme 116: Synthesis of unsymmetrical tetraoxanes using of MeReO3.
Scheme 117: Synthesis of symmetrical tetraoxanes using of MeReO3.
Scheme 118: Synthesis of symmetrical tetraoxanes using of MeReO3.
Scheme 119: MeReO3 in the synthesis of symmetrical tetraoxanes with the use of aldehydes.
Scheme 120: Preparation of unsymmmetrical 1,2,4,5-tetraoxanes with high antimalarial activity.
Scheme 121: Re2O7-Catalyzed synthesis of tetraoxanes 398.
Scheme 122: H2SO4-Catalyzed synthesis of steroidal tetraoxanes 401.
Scheme 123: HBF4-Catalyzed condensation of bishydroperoxide 402 with 1,4-cyclohexanedione.
Scheme 124: BF3·Et2O-Catalyzed reaction of gem-bishydroperoxides 404 with enol ethers 405 and acetals 406.
Scheme 125: HBF4-Catalyzed cyclocondensation of bishydroperoxide 410 with ketones.
Scheme 126: Synthesis of symmetrical and unsymmetrical tetraoxanes 413 from benzaldehydes 412.
Scheme 127: Synthesis of bridged 1,2,4,5-tetraoxanes 415a–l from β-diketones 414a–l and H2O2.
Scheme 128: Dimerization of zwitterions 417.
Scheme 129: Ozonolysis of verbenone 419.
Scheme 130: Ozonolysis of O-methyl oxime 424.
Scheme 131: Peroxidation of 1,1,1-trifluorododecan-2-one 426 with oxone.
Scheme 132: Intramolecular cyclization of dialdehyde 428 with H2O2.
Scheme 133: Tetraoxanes 433–435 as by-products in peroxidation of ketals 430–432.
Scheme 134: Transformation of triperoxide 436 in diperoxide 437.
Scheme 135: Preparation and structural modifications of tetraoxanes.
Scheme 136: Structural modifications of steroidal tetraoxanes.
Scheme 137: Synthesis of 1,2,4,5-tetraoxane 454 containing the fluorescent moiety.
Scheme 138: Synthesis of tetraoxane 458 (RKA182).
Beilstein J. Org. Chem. 2013, 9, 2866–2876, doi:10.3762/bjoc.9.323
Graphical Abstract
Figure 1: Structure of SF002-96-1.
Figure 2: COSY (bold) and HMBC (arrow) correlations of SF002-96-1.
Figure 3: NOESY correlations of SF002-96-1.
Figure 4: Effect of SF002-96-1 on survivin promoter activity, survivin mRNA levels and expression. (A) Colo 3...
Figure 5: Effect of SF002-96-1 on Sat3 and NF-κB binding to the survivin promoter in Colo 320 cells analyzed ...
Figure 6: SF002-96-1 induces apoptosis of Colo 320 cells. (A) Colo 320 cells were treated without (control) o...
Figure 7: Single-quadrupole mass spectrumof SF002-96-1 obtained using an atmospheric pressure chemical ioniza...
Beilstein J. Org. Chem. 2013, 9, 2556–2563, doi:10.3762/bjoc.9.290
Graphical Abstract
Figure 1: Antimycins: Antimycins A1, A2, A3, and A4 and non-natural antimycins referenced in the text. Antimy...
Figure 2: Schematic representation of ant biosynthetic gene clusters. L-form ant gene clusters are encoded by...
Figure 3: Proposed biosynthetic pathway for antimycins. The antimycin biosynthetic pathway is described in de...
Figure 4: σAntA comprises a new subfamily of ECF RNA polymerase σ factors. σAntA amino acid sequences were al...
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 2194–2201, doi:10.3762/bjoc.9.258
Graphical Abstract
Figure 1: Several natural occurring anthracycline antibiotics.
Scheme 1: Total synthesis of daunomycinone 6 according to Hansen.
Scheme 2: Synthesis of simplified anthracycline derivatives.
Scheme 3: Retrosynthetic analysis of anthracycline aglycone mimics. Si: any silyl group.
Scheme 4: Synthetic route for the synthesis of various dialkynes 16. aSi: TMS, SiMe2Bn (2.0 equiv); Si: SiMe2...
Scheme 5: Silyl ether synthesis and domino carbopalladation reaction. R,R (Glc): isopropylidene. R,R (Gal): b...
Scheme 6: Derivatisation of anthracycline derivatives. aR,R (Glc): isopropylidene. R,R (Gal): benzylidene. Re...
Beilstein J. Org. Chem. 2013, 9, 2048–2078, doi:10.3762/bjoc.9.243
Graphical Abstract
Figure 1: a) Structural features and b) selected examples of non-natural congeners.
Scheme 1: Synthesis of isoindole 18.
Scheme 2: Staining amines with 1,4-diketone 19 (R = H).
Figure 2: Representative members of the indolocarbazole alkaloid family.
Figure 3: Staurosporine (26) bound to the adenosine-binding pocket [19] (from pdb1stc).
Figure 4: Structure of imatinib (34) and midostaurin (35).
Scheme 3: Biosynthesis of staurosporine (26).
Scheme 4: Wood’s synthesis of K-252a via the common intermediate 48.
Scheme 5: Synthesis of 26, 27, 49 and 50 diverging from the common intermediate 48.
Figure 5: Selected members of the cytochalasan alkaloid family.
Scheme 6: Biosynthesis of chaetoglobosin A (57) [56].
Scheme 7: Synthesis of cytochalasin D (70) by Thomas [63].
Scheme 8: Synthesis of L-696,474 (78).
Scheme 9: Synthesis of aldehyde 85 (R = TBDPS).
Scheme 10: Synthesis of (+)-aspergillin PZ (79) by Tanis.
Figure 6: Representative Berberis alkaloids.
Scheme 11: Proposed biosynthetic pathway to chilenine (93).
Scheme 12: Synthesis of magallanesine (97) by Danishefsky [84].
Scheme 13: Kurihara’s synthesis of magallanesine (85).
Scheme 14: Proposed biosynthesis of 113, 117 and 125.
Scheme 15: DNA lesion caused by aristolochic acid I (117) [102].
Scheme 16: Snieckus’ synthesis of piperolactam C (131).
Scheme 17: Synthesis of aristolactam BII (104).
Figure 7: Representative cularine alkaloids.
Scheme 18: Proposed biosynthesis of 136.
Scheme 19: The syntheses of 136 and 137 reported by Castedo and Suau.
Scheme 20: Synthesis of 136 by Couture.
Figure 8: Representative isoindolinone meroterpenoids.
Scheme 21: Postulated biosynthetic pathway for the formation of 156 (adopted from George) [143].
Scheme 22: Synthesis of stachyflin (156) by Katoh [144].
Figure 9: Selected examples of spirodihydrobenzofuranlactams.
Scheme 23: Synthesis of stachybotrylactam I (157).
Scheme 24: Synthesis of pestalachloride A (193) by Schmalz.
Scheme 25: Proposed mechanism for the BF3-catalyzed metal-free carbonyl–olefin metathesis [149].
Scheme 26: Preparation of the isoindoline core of muironolide A (204).
Scheme 27: Proposed biosynthesis of 208.
Scheme 28: Model for the biosynthesis of 215 and 217.
Scheme 29: Synthesis of lactonamycin (215) and lactonamycin Z (217).
Figure 10: Hetisine alkaloids 225–228.
Scheme 30: Biosynthetic proposal for the formation of the hetisine core [167].
Scheme 31: Synthesis of nominine (225).
Beilstein J. Org. Chem. 2013, 9, 1677–1695, doi:10.3762/bjoc.9.192
Graphical Abstract
Figure 1: The catalyzed enantioselective desymmetrization.
Figure 2: Cinchona alkaloid-derived catalysts OC-1 to OC-11.
Scheme 1: The enantioselective desymmetrization of meso-aziridines in the presence of selected Cinchona alkal...
Figure 3: Cinchona alkaloid-derived catalysts OC-12 to OC-19.
Scheme 2: The enantioselective ring-opening of aziridines in the presence of OC-16.
Scheme 3: OC-16 catalyzed enantioselective ring-opening of aziridines.
Figure 4: The chiral phosphoric acids catalysts OC-20 and OC-21.
Scheme 4: OC-20 and OC-21 catalyzed enantioselective desymmetrization of meso-aziridines.
Figure 5: The proposed mechanism for chiral phosphorous acid-induced enantioselctive desymmetrization of meso...
Scheme 5: OC-21 catalyzed enantioselective desymmetrization of meso-aziridines by Me3SiSPh.
Scheme 6: OC-21 catalyzed the enantioselective desymmetrization of meso-aziridines by Me3SiSePh/PhSeH.
Figure 6: L-Proline and its derivatives OC-22 to OC-27.
Scheme 7: OC-23 catalyzed enantioselective desymmetrization of meso-aziridines.
Figure 7: Proposed bifunctional mode of action of OC-23.
Figure 8: The chiral thioureas OC-28 to OC-44 for the desymmetrization of meso-aziridines.
Scheme 8: Desymmetrization of meso-aziridines with OC-41.
Figure 9: The chiral guanidines (OC-45 to OC-48).
Scheme 9: OC-46 catalyzed desymmetrization of meso-aziridines by arylthiols.
Scheme 10: Desymmetrization of cis-aziridine-2,3-dicarboxylate.
Figure 10: The proposed activation mode of OC-46.
Scheme 11: The enantioselective desymmetrization of meso-aziridines by amine/CS2 in the presence of OC-46.
Figure 11: The chiral 1,2,3-triazolium chlorides OC-49 to OC-55.
Scheme 12: The enantioselective desymmetrization of meso-aziridines by Me3SiX (X = Cl or Br) in the presence o...
Figure 12: Early organocatalysts for enantioselective desymmetrization of meso-epoxides.
Scheme 13: Attempts of enantioselective desymmetrization of meso-epoxides in the presence of OC-58 or OC-60.
Scheme 14: The enantioselective desymmetrization of a meso-epoxide containing one P atom.
Figure 13: Some chiral phosphoramide and chiral phosphine oxides.
Scheme 15: OC-62 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Figure 14: The proposed mechanism of the chiral HMPA-catalyzed desymmetrization of meso-epoxides.
Scheme 16: The enantioselective desymmetrization of meso-epoxides in the presence of OC-63.
Figure 15: The Chiral phosphine oxides (OC-70 to OC-77) based on an allene backbone.
Scheme 17: OC-73 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Figure 16: Chiral pyridine N-oxides used in enantioselective desymmetrization of meso-epoxides.
Scheme 18: Catalyzed enantioselective desymmetrization of meso-epoxides in the presence of OC-80 or OC-82.
Figure 17: Chiral pyridine N-oxides OC-85 to OC-94.
Scheme 19: Enantioselective desymmetrization of cis-stilbene oxide by using OC-85 to OC-92 as catalysts.
Figure 18: A novel family of helical chiral pyridine N-oxides OC-95 to OC-97.
Scheme 20: Desymmetrization of meso-epoxides catalyzed by OC-95 to OC-97.
Scheme 21: OC-98 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Beilstein J. Org. Chem. 2013, 9, 544–556, doi:10.3762/bjoc.9.60
Graphical Abstract
Figure 1: Design of the biotinylated Hsp90 probes based on PU-H71 (1a).
Scheme 1: Reagents and conditions: (a) D-biotin, DCC, DMAP, CH2Cl2, sonicate; (b) EZ-Link® NHS-LC-Biotin, DIE...
Scheme 2: Reagents and conditions: (a) 6-Boc-aminocaproic acid, DCC, DMAP, CH2Cl2, rt; (b) TFA, CH2Cl2, rt; (...
Figure 2: Analysis of the affinity and selectivity of the biotinylated probes for Hsp90. (a) K562 cancer cell...
Figure 3: Use of probe 2g to detect oncogenic Hsp90 by flow cytometry (a) and (b) and by microscopy (c). For ...